Investigating the role of LSD1 in triple-negative breast cancer and its treatment response
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response
This study is looking at a protein called LSD1 to see how it affects triple-negative breast cancer and hopes to find new ways to make treatments work better for patients dealing with this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11030842 on NIH RePORTER |
What this research studies
This research focuses on understanding how LSD1, a protein that regulates gene expression, contributes to the development and treatment resistance of triple-negative breast cancer (TNBC). By examining the mechanisms behind LSD1 overexpression in TNBC, the study aims to identify new therapeutic strategies that could enhance the effectiveness of existing treatments. Patients with TNBC may benefit from insights gained through this research, as it seeks to develop targeted therapies that address the unique challenges of this aggressive cancer subtype.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may not respond well to current therapies.
Not a fit: Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic factors in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Huang, Yi — University of Iowa
- Study coordinator: Huang, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.